Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of ARGX-113 in mild to moderate pemphigus vulgaris
MOH_2017-12-17_002039Phase 2Completed
- Sponsor
- argenx
- Start
- Nov 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in pemphigus vulgaris (PV), sponsored by argenx. Primary endpoint: Safety and tolerability of ARGX-113. Started Nov 2017; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on MOH_2017-12-17_002039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-12-17_002039.